USA - NASDAQ:OTLK - US69012T3059 - Common Stock
OTLK gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. OTLK may be in some trouble as it scores bad on both profitability and health. OTLK has a valuation in line with the averages, but it does not seem to be growing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -194.01% | ||
| ROE | N/A | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -47.64 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.67 | ||
| Quick Ratio | 0.54 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.42 | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.28
-0.05 (-3.76%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.42 | ||
| Fwd PE | N/A | ||
| P/S | 37.77 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -194.01% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.67 | ||
| Quick Ratio | 0.54 | ||
| Altman-Z | -47.64 |
ChartMill assigns a fundamental rating of 1 / 10 to OTLK.
ChartMill assigns a valuation rating of 4 / 10 to OUTLOOK THERAPEUTICS INC (OTLK). This can be considered as Fairly Valued.
OUTLOOK THERAPEUTICS INC (OTLK) has a profitability rating of 0 / 10.
The Earnings per Share (EPS) of OUTLOOK THERAPEUTICS INC (OTLK) is expected to grow by 30.45% in the next year.